[go: up one dir, main page]

WO1999039006A3 - Methods to identify polynucleotide and polypeptide sequences which may be associated with physiological and medical conditions - Google Patents

Methods to identify polynucleotide and polypeptide sequences which may be associated with physiological and medical conditions Download PDF

Info

Publication number
WO1999039006A3
WO1999039006A3 PCT/US1999/001964 US9901964W WO9939006A3 WO 1999039006 A3 WO1999039006 A3 WO 1999039006A3 US 9901964 W US9901964 W US 9901964W WO 9939006 A3 WO9939006 A3 WO 9939006A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
human
polypeptide sequences
physiological
medical conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/001964
Other languages
French (fr)
Other versions
WO1999039006A2 (en
Inventor
James M Sikela
Walter Messier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genoplex Inc
Original Assignee
Genoplex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genoplex Inc filed Critical Genoplex Inc
Priority to CA002318772A priority Critical patent/CA2318772A1/en
Priority to JP2000529463A priority patent/JP2002501761A/en
Priority to AU24841/99A priority patent/AU769931B2/en
Priority to EP99904442A priority patent/EP1051519A2/en
Publication of WO1999039006A2 publication Critical patent/WO1999039006A2/en
Priority to AU58058/99A priority patent/AU5805899A/en
Priority to PCT/US1999/020209 priority patent/WO2000012764A1/en
Publication of WO1999039006A3 publication Critical patent/WO1999039006A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1072—Differential gene expression library synthesis, e.g. subtracted libraries, differential screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1079—Screening libraries by altering the phenotype or phenotypic trait of the host
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides methods for identifying polynucleotide and polypeptide sequences in human and/or non-human primates which may be associated with a physiological condition, such as disease (including susceptibility (human) or resistance (chimpanzee) to development of AIDS). The methods employ comparison of human and non-human primate sequences using statistical methods. Sequences thus identified may be useful as host therapeutic targets and/or in screening assays.
PCT/US1999/001964 1998-01-30 1999-01-29 Methods to identify polynucleotide and polypeptide sequences which may be associated with physiological and medical conditions Ceased WO1999039006A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002318772A CA2318772A1 (en) 1998-01-30 1999-01-29 Methods to identify polynucleotide and polypeptide sequences which may be associated with physiological and medical conditions
JP2000529463A JP2002501761A (en) 1998-01-30 1999-01-29 Methods for identifying polynucleotide and polypeptide sequences for physiological and medical conditions
AU24841/99A AU769931B2 (en) 1998-01-30 1999-01-29 Methods to identify polynucleotide and polypeptide sequences which may be associated with physiological and medical conditions
EP99904442A EP1051519A2 (en) 1998-01-30 1999-01-29 Methods to identify polynucleotide and polypeptide sequences which may be associated with physiological and medical conditions
AU58058/99A AU5805899A (en) 1998-09-02 1999-09-01 Methods to identify polynucleotide and polypeptide sequences which may be associated with physiological and medical conditions
PCT/US1999/020209 WO2000012764A1 (en) 1998-09-02 1999-09-01 Methods to identify polynucleotide and polypeptide sequences which may be associated with physiological and medical conditions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7326398P 1998-01-30 1998-01-30
US60/073,263 1998-01-30

Publications (2)

Publication Number Publication Date
WO1999039006A2 WO1999039006A2 (en) 1999-08-05
WO1999039006A3 true WO1999039006A3 (en) 1999-11-04

Family

ID=22112723

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/001964 Ceased WO1999039006A2 (en) 1998-01-30 1999-01-29 Methods to identify polynucleotide and polypeptide sequences which may be associated with physiological and medical conditions

Country Status (4)

Country Link
EP (1) EP1051519A2 (en)
JP (1) JP2002501761A (en)
CA (1) CA2318772A1 (en)
WO (1) WO1999039006A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6866996B1 (en) 1998-01-30 2005-03-15 Evolutionary Genomics, Llc Methods to identify polynucleotide and polypeptide sequences which may be associated with physiological and medical conditions
US7247425B2 (en) 1998-01-30 2007-07-24 Evolutionary Genomics, Llc Methods to identify polynucleotide and polypeptide sequences which may be associated with physiological and medical conditions
US6280953B1 (en) * 1998-01-30 2001-08-28 Evolutionary Genomics, L.L.C. Methods to identify polynucleotide and polypeptide sequences which may be associated with physiological and medical conditions
WO2005024066A1 (en) * 2003-06-30 2005-03-17 Evolutionary Genomics Llc Methods to identify polynucleotide and polypeptide sequences which may be associated with physiological and medical conditions

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BURGER H. ET AL.,: "Molecular evolution of interleukin-3", J. MOL. EVOL., vol. 39, no. 3, - September 1994 (1994-09-01), pages 255 - 267, XP002114680 *
HERBERT G. & EASTEAL S.: "Relative rates of nuclear DNA evolution in human and old world monkey lineages", MOL. BIOL. EVOL., vol. 13, no. 7, - September 1996 (1996-09-01), pages 1054 - 1057, XP002114698 *
JAEGER E. ET AL.,: "Structure, diversity, and evolution of the T-cell receptor VB gene repertoire in primates", IMMUNOGENETICS, vol. 40, no. 3, - 1994, pages 184 - 191, XP002114681 *
LEE M.E. ET AL.,: "Molecular cloning and expression of rhesus macaque and sooty mangabey interleukin 16: biologic activity and effect on simian immunodeficiency virus infection and/or replication", AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 14, no. 15, - 15 October 1998 (1998-10-15), pages 1323 - 1328, XP002114679 *
LYN D. ET AL.,: "Conservation of sequences between human and gorilla lineages: ADP-ribosyltransferase(NAD+) pseudogene 1 and neighboring retroposons", GENE, vol. 155, - 1995, pages 241 - 245, XP002114678 *
MESSIER W. & STEWART C.-B.: "Episodic adaptive evolution of primate lysozymes", NATURE, vol. 385, - 9 January 1997 (1997-01-09), pages 151 - 154, XP002114682 *

Also Published As

Publication number Publication date
JP2002501761A (en) 2002-01-22
EP1051519A2 (en) 2000-11-15
CA2318772A1 (en) 1999-08-05
WO1999039006A2 (en) 1999-08-05

Similar Documents

Publication Publication Date Title
WO2004028339A3 (en) Treatment of patients with multiple sclerosis based on gene expression changes in central nervous system tissues
CA2274596A1 (en) Compositions and methods for enhancing intestinal function
WO2004020968A3 (en) Mutations in nod2 are associated with fibrostenosing disease in patients with crohn’s disease
EP1373567A4 (en) "DETECTION OF SEQUENCES RICH IN METHYLATED CPG FOR THE DIAGNOSIS OF MALIGNER CELLS"
WO2005114190A3 (en) Methods of identifying biomarkers
EP2322628A3 (en) Mutations in the BCR-ABL tyrosine kinase associated with resistance to STI-571
WO2003095618A3 (en) Identification of dysregulated genes in patients with multiple sclerosis
WO2000018954A3 (en) Use of pex in the treatment of metabolic bone diseases
MXPA03001930A (en) Tnf receptor-like molecules and uses thereof.
Reisberg et al. Diagnosis of Alzheimer's disease: report of an international psychogeriatric association special meeting work group under the cosponsorship of Alzheimer's disease international, the European federation of neurological societies, the World Health Organization, and the World Psychiatric Association
EP2329827A3 (en) Methods and immune modulatory nucleic acid compositions for preventing and treating disease
WO2001096603A3 (en) Methods to identify polynucleotide and polypeptide sequences which may be associated with physiological and medical conditions
WO2000034511A3 (en) Aβ-PEPTIDE SCREENING ASSAY
WO2003054166A3 (en) Nucleotide polymorphisms associated with osteoarthritis
WO1999066075A3 (en) Diagnostic method based on quantification of extramitochondrial dna
WO1999039006A3 (en) Methods to identify polynucleotide and polypeptide sequences which may be associated with physiological and medical conditions
WO2002010388A3 (en) C3b/C4b COMPLEMENT RECEPTOR-LIKE MOLECULES AND USES THEREOF
AU2932100A (en) Neurodegenerative disorder related gene
WO2004087752A3 (en) Spinster-like protein genes, expression products, non-human animal model: uses in human metabolic disorders
WO2001079272A3 (en) Sitosterolemia susceptibility gene (ssg): compositions and methods of use
WO2001077305A3 (en) Variants of the human amp-activated protein kinase gamma 3 subunit
BR0014167A (en) Proteìna iren, its preparation and application
EP2048235A3 (en) Synthetic Mammalian Alpha-N-Acetylglucosaminidase and Genetic Sequences Encoding Same
ATE337020T1 (en) FATTY ACID ANALOGUES FOR THE DIAGNOSIS OF CRONY ARTERY DISEASES
WO2004074514A3 (en) Method of diagnosis of type 2 diabetes and early onset thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref document number: 2318772

Country of ref document: CA

Ref country code: CA

Ref document number: 2318772

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 24841/99

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: KR

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 529463

Kind code of ref document: A

Format of ref document f/p: F

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1999904442

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999904442

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 24841/99

Country of ref document: AU